Nektar Therapeutics Stock Price, News & Analysis (NASDAQ:NKTR)

$71.59 1.43 (2.04 %)
(As of 01/21/2018 04:00 PM ET)
Previous Close$71.59
Today's Range$69.62 - $72.18
52-Week Range$11.41 - $75.33
Volume3.69 million shs
Average Volume2.02 million shs
Market Capitalization$11.27 billion
P/E Ratio-99.43
Dividend YieldN/A
Beta1.81

About Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics logoNektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

Receive NKTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:NKTR
CUSIP64026810
Phone415-482-5300

Debt

Debt-to-Equity Ratio2.91%
Current Ratio4.14%
Quick Ratio3.99%

Price-To-Earnings

Trailing P/E Ratio-99.4305555555556
Forward P/E Ratio-94.20
P/E GrowthN/A

Sales & Book Value

Annual Sales$165.44 million
Price / Sales68.14
Cash FlowN/A
Price / CashN/A
Book Value$0.58 per share
Price / Book123.43

Profitability

Trailing EPS($0.72)
Net Income$-153,520,000.00
Net Margins-42.08%
Return on Equity-190.68%
Return on Assets-19.50%

Miscellaneous

Employees468
Outstanding Shares157,470,000

Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) released its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.21 by $0.16. The biopharmaceutical company had revenue of $152.90 million for the quarter, compared to analyst estimates of $126.50 million. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The company's revenue was up 321.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.32) EPS. View Nektar Therapeutics' Earnings History.

When will Nektar Therapeutics make its next earnings announcement?

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Nektar Therapeutics.

Where is Nektar Therapeutics' stock going? Where will Nektar Therapeutics' stock price be in 2018?

13 Wall Street analysts have issued 12 month price objectives for Nektar Therapeutics' stock. Their forecasts range from $20.00 to $88.00. On average, they expect Nektar Therapeutics' stock price to reach $44.18 in the next twelve months. View Analyst Ratings for Nektar Therapeutics.

What are Wall Street analysts saying about Nektar Therapeutics stock?

Here are some recent quotes from research analysts about Nektar Therapeutics stock:

  • 1. According to Zacks Investment Research, "Nektar has a promising pipeline, with several updates lined up for the next several quarters. Additionally, regular partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone payment plus royalties for Movantik under the license agreement with AstraZeneca. Also, its recent co-development deal with Lilly for NKTR-358 is encouraging. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company, while disappointing products sales could leave an adverse impact on its financial results. Moreover, competition from various pharmaceutical and biotechnology companies is another matter of concern. Shares of the company have significantly outperformed the industry in the last one year." (1/16/2018)
  • 2. Mizuho analysts commented, "We believe raising our PT from $30 to $45 more accurately reflects conservative assumptions surrounding the value add of NKTR-214 within US- based NSCLC patients. Going forward, we believe NKTR-214 will remain a major value driver for the company." (11/8/2017)
  • 3. BTIG Research analysts commented, "Nektar announced positive results from the Phase 3 SUMMIT-07 study of NKTR-181, its novel, proprietary, abuse-resistant opioid for pain. NKTR- 181 met all important primary and secondary efficacy endpoints in the 610- patient study, and the molecule appeared well tolerated, materially derisking the program. At its primary endpoint at week 12 postrandomization, average pain scores increased 1.46 points on the Numeric Rating Scale with placebo, vs. 0.92 points for NKTR-181 (p=0.0019); other secondary endpoints were also as positive. NKTR-181 has been FastTracked, a rarity for an opioid, and with this highly positive study in hand, there is a possibility for rapid progression of NKTR-181, and a material partnership. With 181's success, and with the potential for additional meaningful catalysts near-term, we raise our NKTR price target to $27." (3/21/2017)
  • 4. Jefferies Group LLC analysts commented, "The unexpected Ph 3 success for '181 brings this once very promising mu-opioid analgesic asset back to life. In our view, it could become NKTR's largest and most profitable product as it squarely addresses the 'opioid epidemic'. Mgt hopes to partner the drug by YE. We believe '181 could bring significant value (modeling 30% royalties and $250M+ in milestones) to the company as early as 2020. With this asset now unencumbered, NKTR now fits our M&A thesis." (3/21/2017)
  • 5. Aegis analysts commented, "NKTR-181 met its primary endpoint in the phase III Summit-07 trial - increase Price Target to $25. Yesterday morning, Netkar Therapeutics announced that NKTR-181 met its primary endpoint of mean change in weekly average numeric rating scale (NRS) pain score for the randomized, double-blind treatment period from the end of the open-label titration period (baseline) to week 12. Average pain scores measured at week 12 from baseline increased 1.46 for placebo vs. 0.92 for NKTR-181 (p=0.0019). We had not previously factored in revenue from NKTR-181 into our price target. As a result of the positive phase III results, we now include such revenue under partnering assumptions in the US and raise our price target from $21 to $24." (3/20/2017)

Who are some of Nektar Therapeutics' key competitors?

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the folowing people:

  • Robert B. Chess, Independent Chairman of the Board (Age 60)
  • Howard W. Robin, President, Chief Executive Officer, Director (Age 64)
  • Gilbert M. Labrucherie J.D., Chief Financial Officer, Senior Vice President (Age 45)
  • John L. Nicholson, Chief Operating Officer, Senior Vice President (Age 65)
  • Jillian B. Thomsen, Senior Vice President - Finance, Chief Accounting Officer (Age 51)
  • Jonathan Zalevsky, Senior Vice President - Research , Chief Scientific Officer
  • Stephen K. Doberstein Ph.D., Senior Vice President, Research & Development and Chief Research & Development Officer (Age 58)
  • Ivan Philip Gergel M.D., Senior Vice President - Drug Development & Chief Medical Officer (Age 56)
  • Maninder Hora Ph.D., Senior Vice President - Pharmaceutical Development and Manufacturing Operations (Age 63)
  • Mary Tagliaferri M.D., Senior Vice President - Clinical Development and Chief Medical Officer (Age 47)

Who owns Nektar Therapeutics stock?

Nektar Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.51%), Louisiana State Employees Retirement System (0.04%) and Sicart Associates LLC (0.00%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.

Who bought Nektar Therapeutics stock? Who is buying Nektar Therapeutics stock?

Nektar Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Louisiana State Employees Retirement System and Sicart Associates LLC. Company insiders that have bought Nektar Therapeutics stock in the last two years include R Scott Greer and Roy A Whitfield. View Insider Buying and Selling for Nektar Therapeutics.

How do I buy Nektar Therapeutics stock?

Shares of Nektar Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nektar Therapeutics' stock price today?

One share of Nektar Therapeutics stock can currently be purchased for approximately $71.59.

How big of a company is Nektar Therapeutics?

Nektar Therapeutics has a market capitalization of $11.27 billion and generates $165.44 million in revenue each year. The biopharmaceutical company earns $-153,520,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Nektar Therapeutics employs 468 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]


MarketBeat Community Rating for Nektar Therapeutics (NKTR)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  364 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  519
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nektar Therapeutics (NASDAQ:NKTR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.922.922.903.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $44.18$36.64$27.11$26.29
Price Target Upside: 38.64% downside18.46% downside18.23% upside18.56% upside

Nektar Therapeutics (NASDAQ:NKTR) Consensus Price Target History

Price Target History for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018Jefferies GroupBoost Price TargetBuy$2.12 -> $88.00HighView Rating Details
1/10/2018Canaccord GenuityReiterated RatingBuy$50.00 -> $80.00LowView Rating Details
11/15/2017Canaccord Genuity GroupBoost Price TargetBuy$35.00 -> $50.00N/AView Rating Details
11/13/2017Roth CapitalSet Price TargetBuy$45.00N/AView Rating Details
11/14/2017MizuhoBoost Price TargetBuy$30.00 -> $45.00N/AView Rating Details
11/13/2017JPMorgan Chase & Co.Reiterated RatingPositive -> Buy$44.00N/AView Rating Details
11/7/2017CowenInitiated CoverageOutperformN/AView Rating Details
8/17/2017Evercore ISIInitiated CoverageIn -> In-Line$20.00HighView Rating Details
8/7/2017HC WainwrightInitiated CoverageBuy -> Buy$31.00LowView Rating Details
7/18/2017William BlairReiterated RatingOutperformLowView Rating Details
5/10/2017AegisReiterated RatingBuy$27.00HighView Rating Details
4/11/2017Piper Jaffray CompaniesReiterated RatingOverweight$29.00LowView Rating Details
3/21/2017BTIG ResearchBoost Price TargetPositive$22.00 -> $27.00MediumView Rating Details
9/30/2016Brean CapitalReiterated RatingBuy$23.00N/AView Rating Details
1/27/2016Janney Montgomery ScottInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 1/21/2016 forward)

Earnings

Nektar Therapeutics (NASDAQ:NKTR) Earnings History and Estimates Chart

Earnings by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ NKTR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($0.33)N/AView Earnings Details
11/7/2017Q3 2017$0.21$0.37$126.50 million$152.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.35)($0.39)$33.64 million$34.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.40)($0.42)$29.43 million$24.73 millionViewListenView Earnings Details
3/1/2017Q416($0.26)($0.28)$40.83 million$37.45 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.32)$32.42 million$36.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.36)$34.17 million$32.77 millionViewListenView Earnings Details
5/3/2016Q1($0.23)($0.14)$43.78 million$58.88 millionViewN/AView Earnings Details
3/1/2016Q4($0.42)($0.40)$28.82 million$39.40 millionViewListenView Earnings Details
11/5/2015Q315($0.30)($0.06)$44.30 million$60.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.40)$21.49 million$22.66 millionViewN/AView Earnings Details
4/30/2015Q115($0.40)$0.25$20.20 million$108.80 millionViewN/AView Earnings Details
2/24/2015Q414($0.36)($0.35)$12.30 million$19.55 millionViewN/AView Earnings Details
11/6/2014Q314$0.39$0.53$123.20 million$132.90 millionViewN/AView Earnings Details
7/31/2014Q214($0.38)($0.26)$19.76 million$28.50 millionViewListenView Earnings Details
5/7/2014Q114($0.35)($0.37)$38.68 million$19.80 millionViewListenView Earnings Details
2/26/2014Q413($0.17)($0.41)$49.26 million$31.15 millionViewN/AView Earnings Details
11/7/2013Q313($0.22)($0.14)$54.34 million$60.91 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.44)($0.37)$26.22 million$33.86 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.48)$26.30 million$23.00 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.45)($0.46)ViewN/AView Earnings Details
11/9/2012Q312($0.39)($0.38)$21.02 million$18.41 millionViewN/AView Earnings Details
8/9/2012($0.33)($0.30)ViewN/AView Earnings Details
5/2/2012($0.33)($0.36)ViewN/AView Earnings Details
2/29/2012($0.47)($0.33)ViewN/AView Earnings Details
11/2/2011($0.37)($0.21)ViewN/AView Earnings Details
8/4/2011($0.31)($0.32)ViewN/AView Earnings Details
4/27/2011($0.27)($0.33)ViewN/AView Earnings Details
3/1/2011Q4 2010($0.16)($0.11)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.05)($0.09)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.09)($0.01)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.09)($0.07)ViewN/AView Earnings Details
3/2/2010Q4 2009$0.08($0.08)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.40)($0.33)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.42)($0.35)ViewN/AView Earnings Details
5/6/2009Q1 2009($0.41)($0.34)ViewN/AView Earnings Details
2/24/2009Q4 2008($0.31)($0.46)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.29)($0.40)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.31)($0.36)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.27)($0.44)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.25)($0.13)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Nektar Therapeutics (NASDAQ:NKTR) Earnings Estimates

2018 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.32)($0.12)($0.22)
Q2 20182($0.32)($0.13)($0.23)
Q3 20182($0.33)($0.13)($0.23)
Q4 20181($0.33)($0.33)($0.33)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Nektar Therapeutics (NASDAQ:NKTR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Nektar Therapeutics (NASDAQ NKTR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 96.01%
Insider Trades by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ NKTR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Christopher A KueblerDirectorSell30,000$58.66$1,759,800.0070,500View SEC Filing  
12/13/2017Howard W RobinCEOSell83,333$55.69$4,640,814.77272,768View SEC Filing  
11/13/2017John NicholsonCOOSell15,910$37.78$601,079.80249,066View SEC Filing  
11/8/2017Stephen K DobersteinSVPSell396,323$29.00$11,493,367.0052,016View SEC Filing  
11/6/2017Maninder HoraSVPSell5,117$25.07$128,283.1952,016View SEC Filing  
11/1/2017Howard W RobinCEOSell83,334$23.57$1,964,182.38235,838View SEC Filing  
10/9/2017Howard W RobinCEOSell83,333$24.20$2,016,658.60View SEC Filing  
10/5/2017Stephen K DobersteinSVPSell43,677$24.97$1,090,614.69View SEC Filing  
10/2/2017Gil M. LabrucherieCFOSell120,000$24.45$2,934,000.00View SEC Filing  
10/2/2017Ivan P GergelSVPSell100,000$24.14$2,414,000.0084,871View SEC Filing  
9/22/2017Christopher A KueblerDirectorSell4,000$21.86$87,440.0040,500View SEC Filing  
9/21/2017Robert ChessDirectorSell6,400$21.72$139,008.00274,223View SEC Filing  
9/6/2017Howard W RobinCEOSell83,333$21.54$1,794,992.82235,837View SEC Filing  
8/16/2017Howard W RobinCEOSell91,714$19.26$1,766,411.64152,504View SEC Filing  
8/16/2017Jillian B. ThomsenCAOSell2,648$19.32$51,159.36View SEC Filing  
8/16/2017John NicholsonCOOSell3,177$19.32$61,379.64224,066View SEC Filing  
8/16/2017Stephen K DobersteinSVPSell1,701$19.32$32,863.3231,102View SEC Filing  
8/10/2017Roy A WhitfieldDirectorBuy35,000$17.95$628,250.00133,000View SEC Filing  
7/18/2017Ivan P GergelSVPSell54,920$21.10$1,158,812.0098,492View SEC Filing  
7/14/2017Lutz LingnauDirectorSell30,000$20.76$622,800.0053,450View SEC Filing  
7/12/2017Ivan P GergelSVPSell45,080$21.08$950,286.4051,961View SEC Filing  
7/11/2017Ivan P GergelSVPSell8,389$21.04$176,504.5651,961View SEC Filing  
5/16/2017Gil M. LabrucherieCFOSell3,179$19.55$62,149.45View SEC Filing  
5/16/2017Howard W RobinCEOSell8,388$19.55$163,985.40160,884View SEC Filing  
5/16/2017John NicholsonCOOSell3,146$19.55$61,504.30178,943View SEC Filing  
5/16/2017Stephen K DobersteinSVPSell1,701$19.55$33,254.5532,803View SEC Filing  
5/15/2017Robert ChessDirectorSell5,000$19.79$98,950.00276,623View SEC Filing  
4/17/2017Robert ChessDirectorSell5,000$18.72$93,600.00276,623View SEC Filing  
4/7/2017Lutz LingnauDirectorSell7,000$20.05$140,350.0023,450View SEC Filing  
4/5/2017Christopher A KueblerDirectorSell15,000$21.88$328,200.0050,500View SEC Filing  
4/5/2017Maninder HoraSVPSell180,000$21.70$3,906,000.00View SEC Filing  
3/20/2017Jillian B. ThomsenSVPSell112,500$19.69$2,215,125.00View SEC Filing  
3/3/2017Gil M. LabrucherieCFOSell200,000$15.16$3,032,000.00View SEC Filing  
2/16/2017Gil M. LabrucherieCFOSell2,359$13.14$30,997.26View SEC Filing  
2/16/2017Howard W RobinCEOSell8,636$13.14$113,477.04169,272View SEC Filing  
2/16/2017Ivan P GergelSVPSell1,457$13.14$19,144.9845,022View SEC Filing  
2/16/2017John NicholsonCOOSell3,237$13.14$42,534.18182,089View SEC Filing  
2/8/2017Howard W RobinCEOSell87,500$13.04$1,141,000.00265,408View SEC Filing  
2/3/2017John NicholsonCOOSell75,000$12.39$929,250.00206,821View SEC Filing  
1/17/2017Howard W RobinCEOSell87,500$12.35$1,080,625.00265,408View SEC Filing  
11/17/2016Howard W RobinCEOSell93,458$13.88$1,297,197.04122,908View SEC Filing  
10/24/2016R Scott GreerDirectorBuy15,000$13.50$202,500.00121,333View SEC Filing  
10/4/2016Howard W. RobinCEOSell87,500$17.06$1,492,750.00View SEC Filing  
9/16/2016Christopher A. KueblerDirectorSell7,500$19.13$143,475.00View SEC Filing  
9/15/2016Robert ChessDirectorSell12,000$19.21$230,520.00View SEC Filing  
9/1/2016Howard W. RobinCEOSell87,500$17.83$1,560,125.00View SEC Filing  
8/16/2016Gil M. LabrucherieCFOSell3,305$17.56$58,035.80View SEC Filing  
8/16/2016Howard W. RobinCEOSell11,817$17.56$207,506.52View SEC Filing  
8/16/2016John NicholsonCOOSell3,317$17.56$58,246.52View SEC Filing  
8/16/2016Stephen K. DobersteinSVPSell1,336$17.56$23,460.16View SEC Filing  
8/1/2016Robert ChessDirectorSell5,000$17.26$86,300.00View SEC Filing  
7/11/2016Jillian B ThomsenCAOSell100,000$15.09$1,509,000.00106,809View SEC Filing  
7/1/2016Robert ChessDirectorSell5,000$14.10$70,500.00View SEC Filing  
5/17/2016Gil M LabrucherieSVPSell836$13.58$11,352.888,757View SEC Filing  
5/17/2016Howard W RobinCEOSell2,170$13.58$29,468.6019,103View SEC Filing  
5/17/2016Jillian B ThomsenCAOSell724$13.58$9,831.927,033View SEC Filing  
5/17/2016John NicholsonCFOSell856$13.58$11,624.4878,486View SEC Filing  
4/25/2016Lutz LingnauDirectorSell15,000$16.27$244,050.0031,450View SEC Filing  
2/17/2016Howard W. RobinCEOSell2,147$11.92$25,592.2413,478View SEC Filing  
2/17/2016Jillian B. ThomsenCAOSell716$11.92$8,534.725,158View SEC Filing  
2/17/2016Maninder HoraSVPSell963$11.92$11,478.965,803View SEC Filing  
2/10/2016Gil M. LabrucherieSVPSell11,666$11.49$134,042.345,251View SEC Filing  
2/10/2016Howard W. RobinCEOSell66,666$11.49$765,992.3410,000View SEC Filing  
2/10/2016Jillian B. ThomsenCAOSell15,000$11.49$172,350.003,999View SEC Filing  
1/20/2016Lutz LingnauDirectorSell15,000$14.51$217,650.0016,450View SEC Filing  
1/19/2016Gil M. LabrucherieSVPSell11,667$14.12$164,738.045,251View SEC Filing  
1/19/2016Howard W. RobinCEOSell66,667$14.12$941,338.0410,000View SEC Filing  
1/19/2016Jillian B. ThomsenCAOSell15,000$14.12$211,800.003,999View SEC Filing  
12/4/2015Christopher A. KueblerDirectorSell15,000$15.82$237,300.0020,000View SEC Filing  
12/3/2015Gil M. LabrucherieSVPSell45,001$15.87$714,165.875,251View SEC Filing  
12/3/2015Howard W. RobinCEOSell125,001$15.87$1,983,765.8710,000View SEC Filing  
12/3/2015Jillian B. ThomsenCAOSell15,000$15.87$238,050.003,999View SEC Filing  
11/20/2015Susan WangDirectorSell85,000$15.02$1,276,700.0020,000View SEC Filing  
11/11/2015Gil M. LabrucherieSVPSell45,000$13.52$608,400.004,751View SEC Filing  
11/11/2015Howard W. RobinCEOSell125,000$13.52$1,690,000.0010,000View SEC Filing  
11/11/2015Jillian B. ThomsenCAOSell15,000$13.52$202,800.003,499View SEC Filing  
10/28/2015Lutz LingnauDirectorSell12,500$12.00$150,000.0016,450View SEC Filing  
10/6/2015Gil M. LabrucherieSVPSell45,000$10.99$494,550.004,751View SEC Filing  
10/6/2015Howard W. RobinCEOSell125,000$10.99$1,373,750.0010,000View SEC Filing  
10/6/2015Jillian B. ThomsenCAOSell15,000$10.99$164,850.003,499View SEC Filing  
9/23/2015Gil M. LabrucherieSVPSell44,999$13.04$586,786.964,751View SEC Filing  
9/23/2015Howard W. RobinCEOSell124,999$13.04$1,629,986.9610,000View SEC Filing  
9/23/2015Jillian B. ThomsenCAOSell10,000$13.04$130,400.003,499View SEC Filing  
8/13/2015Gil M LabrucherieSVPSell33,333$10.89$362,996.37View SEC Filing  
8/13/2015Howard W RobinCEOSell58,333$10.89$635,246.37View SEC Filing  
7/14/2015Gil M LabrucherieSVPSell33,334$11.78$392,674.52View SEC Filing  
7/14/2015Howard W RobinCEOSell58,334$11.78$687,174.52View SEC Filing  
6/29/2015Susan WangDirectorSell30,000$12.70$381,000.00View SEC Filing  
6/19/2015Robert ChessDirectorSell15,000$11.81$177,150.00View SEC Filing  
6/15/2015Lutz LingnauDirectorSell25,000$11.15$278,750.00View SEC Filing  
12/29/2014Robert ChessDirectorSell29,500$15.34$452,530.00View SEC Filing  
12/22/2014Jillian B ThomsenCAOSell5,000$15.56$77,800.00View SEC Filing  
12/1/2014Gil M LabrucherieSVPSell120,000$17.02$2,042,400.00View SEC Filing  
12/1/2014Howard W RobinCEOSell350,000$17.01$5,953,500.00View SEC Filing  
11/25/2014Howard W RobinCEOSell600,000$15.25$9,150,000.00View SEC Filing  
11/24/2014Gil M LabrucherieSVPSell10,500$15.04$157,920.00View SEC Filing  
11/24/2014Howard W RobinCEOSell132,800$15.02$1,994,656.00View SEC Filing  
11/24/2014Lutz LingnauDirectorSell15,000$15.02$225,300.00View SEC Filing  
11/3/2014Gil M LabrucherieSVPSell9,900$13.78$136,422.00View SEC Filing  
8/5/2013Roy WhitfieldDirectorSell12,500$12.41$155,125.0020,000View SEC Filing  
9/14/2012Dennis L WingerDirectorBuy5,000$9.18$45,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Nektar Therapeutics (NASDAQ NKTR) News Headlines

Source:
DateHeadline
Heres Why Nektar Stock Skyrocketed Almost 500% in a YearHere's Why Nektar Stock Skyrocketed Almost 500% in a Year
www.zacks.com - January 19 at 10:45 AM
Here's Why Nektar Stock Skyrocketed Almost 500% in a YearHere's Why Nektar Stock Skyrocketed Almost 500% in a Year
finance.yahoo.com - January 19 at 10:45 AM
Nektar Therapeutics to Post FY2022 Earnings of ($0.67) Per Share, Jefferies Group Forecasts (NKTR)Nektar Therapeutics to Post FY2022 Earnings of ($0.67) Per Share, Jefferies Group Forecasts (NKTR)
www.americanbankingnews.com - January 18 at 11:32 PM
Nektar Therapeutics Expected to Earn FY2017 Earnings of ($0.84) Per Share (NKTR)Nektar Therapeutics Expected to Earn FY2017 Earnings of ($0.84) Per Share (NKTR)
www.americanbankingnews.com - January 18 at 6:44 AM
Nektar Boasts Strong Pipeline, Competition Remains a WoeNektar Boasts Strong Pipeline, Competition Remains a Woe
www.zacks.com - January 17 at 9:30 AM
Nektar Therapeutics (NKTR) Upgraded to "Hold" by Zacks Investment ResearchNektar Therapeutics (NKTR) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - January 16 at 11:54 AM
Shire granted EU marketing authorization for ADYNOVI® [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia AShire granted EU marketing authorization for ADYNOVI® [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia A
feeds.benzinga.com - January 15 at 5:12 AM
Stock Traders Purchase Large Volume of Nektar Therapeutics Put Options (NKTR)Stock Traders Purchase Large Volume of Nektar Therapeutics Put Options (NKTR)
www.americanbankingnews.com - January 13 at 3:15 AM
Notable Wednesday Option Activity: ELLI, NKTR, FNotable Wednesday Option Activity: ELLI, NKTR, F
www.nasdaq.com - January 10 at 5:11 PM
Nektar Therapeutics (NKTR) and Alkermes (ALKS) Head to Head ContrastNektar Therapeutics (NKTR) and Alkermes (ALKS) Head to Head Contrast
www.americanbankingnews.com - January 10 at 1:18 PM
Nektar Therapeutics (NKTR) "Buy" Rating Reaffirmed at Canaccord GenuityNektar Therapeutics' (NKTR) "Buy" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - January 10 at 11:32 AM
Today’s Research Reports on Trending Tickers: Array BioPharma and Nektar TherapeuticsToday’s Research Reports on Trending Tickers: Array BioPharma and Nektar Therapeutics
finance.yahoo.com - January 10 at 9:41 AM
Tuesdays ETF Movers: FBT, GDXJTuesday's ETF Movers: FBT, GDXJ
www.nasdaq.com - January 9 at 5:18 PM
$39.14 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter$39.14 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter
www.americanbankingnews.com - January 9 at 12:40 PM
Nektar Therapeutics (NKTR) Expected to Post Earnings of -$0.35 Per ShareNektar Therapeutics (NKTR) Expected to Post Earnings of -$0.35 Per Share
www.americanbankingnews.com - January 7 at 7:22 AM
Better Buy for 2018: Cara Therapeutics or Nektar Therapeutics?Better Buy for 2018: Cara Therapeutics or Nektar Therapeutics?
www.fool.com - January 6 at 12:53 PM
Christopher A. Kuebler Sells 30,000 Shares of Nektar Therapeutics (NKTR) StockChristopher A. Kuebler Sells 30,000 Shares of Nektar Therapeutics (NKTR) Stock
www.americanbankingnews.com - January 4 at 7:02 PM
Nektar Therapeutics President and CEO, Howard Robin, To Present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CANektar Therapeutics' President and CEO, Howard Robin, To Present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
finance.yahoo.com - January 3 at 8:49 AM
Nektar Therapeutics (NKTR) Given Average Rating of "Buy" by AnalystsNektar Therapeutics (NKTR) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 2 at 8:26 AM
JPMorgan Chase & Co. Reiterates "Buy" Rating for Nektar Therapeutics (NKTR)JPMorgan Chase & Co. Reiterates "Buy" Rating for Nektar Therapeutics (NKTR)
www.americanbankingnews.com - December 31 at 5:08 PM
ETFs with exposure to Nektar Therapeutics : December 28, 2017ETFs with exposure to Nektar Therapeutics : December 28, 2017
finance.yahoo.com - December 28 at 3:51 PM
Nektar Therapeutics :NKTR-US: Earnings Analysis: Q3, 2017 By the Numbers : December 28, 2017Nektar Therapeutics :NKTR-US: Earnings Analysis: Q3, 2017 By the Numbers : December 28, 2017
finance.yahoo.com - December 28 at 10:29 AM
Zacks: Analysts Expect Nektar Therapeutics (NKTR) Will Post Quarterly Sales of $39.14 MillionZacks: Analysts Expect Nektar Therapeutics (NKTR) Will Post Quarterly Sales of $39.14 Million
www.americanbankingnews.com - December 23 at 2:25 AM
Nektar Therapeutics (NKTR) Has Climbed To A New High For The YearNektar Therapeutics (NKTR) Has Climbed To A New High For The Year
www.nasdaq.com - December 22 at 9:05 PM
Why is Nektar (NKTR) Stock Up More Than 350% This Year?Why is Nektar (NKTR) Stock Up More Than 350% This Year?
finance.yahoo.com - December 22 at 9:44 AM
Nektar Therapeutics: Could Improved FDA Policies Help NKTR-181? - Seeking AlphaNektar Therapeutics: Could Improved FDA Policies Help NKTR-181? - Seeking Alpha
seekingalpha.com - December 19 at 5:12 PM
Nektar Therapeutics (NKTR) CEO Sells $4,640,814.77 in StockNektar Therapeutics (NKTR) CEO Sells $4,640,814.77 in Stock
www.americanbankingnews.com - December 15 at 8:52 PM
Nektar Therapeutics down 1% premarket after Bayer bails on agreement to develop inhaled amikacinNektar Therapeutics down 1% premarket after Bayer bails on agreement to develop inhaled amikacin
seekingalpha.com - December 15 at 8:34 AM
Notable Upside Options Positioning in Nektar Therapeutics (NKTR) Highlights Speculative Bullish Bias Over the Next Month -Susquehanna'Notable Upside Options Positioning' in Nektar Therapeutics (NKTR) Highlights 'Speculative Bullish Bias' Over the Next Month -Susquehanna
www.streetinsider.com - December 14 at 9:45 AM
Notable Upside Options Positioning in Nektar Therapeutics (NKTR) Highlights Speculative Bullish Bias Over the ... - StreetInsider.com'Notable Upside Options Positioning' in Nektar Therapeutics (NKTR) Highlights 'Speculative Bullish Bias' Over the ... - StreetInsider.com
www.streetinsider.com - December 13 at 5:22 PM
Nektar Therapeutics to Host Earnings CallNektar Therapeutics to Host Earnings Call
finance.yahoo.com - December 11 at 5:26 PM
Strange: Bullish NKTR Analysts Actually See -28.11% DownsideStrange: Bullish NKTR Analysts Actually See -28.11% Downside
www.nasdaq.com - December 11 at 10:22 AM
Notable BioSci Mover On Dec 7, 2017 - Nektar Therapeutics - Seeking AlphaNotable BioSci Mover On Dec 7, 2017 - Nektar Therapeutics - Seeking Alpha
seekingalpha.com - December 10 at 9:35 AM
Head to Head Survey: AC Immune (ACIU) versus Nektar Therapeutics (NKTR)Head to Head Survey: AC Immune (ACIU) versus Nektar Therapeutics (NKTR)
www.americanbankingnews.com - December 9 at 3:14 AM
Can Nektar Therapeutics (NKTR) Run Higher on Strong Earnings Estimate Revisions? - NasdaqCan Nektar Therapeutics (NKTR) Run Higher on Strong Earnings Estimate Revisions? - Nasdaq
www.nasdaq.com - December 8 at 9:36 AM
Today’s Research Reports on Stocks to Watch: Sage Therapeutics and Nektar TherapeuticsToday’s Research Reports on Stocks to Watch: Sage Therapeutics and Nektar Therapeutics
finance.yahoo.com - December 8 at 9:36 AM
Nektar Therapeutics (NKTR) Given Consensus Rating of "Buy" by BrokeragesNektar Therapeutics (NKTR) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 8 at 8:22 AM
Can Nektar Therapeutics (NKTR) Run Higher on Strong Earnings Estimate Revisions?Can Nektar Therapeutics (NKTR) Run Higher on Strong Earnings Estimate Revisions?
finance.yahoo.com - December 7 at 9:54 AM
Why Nektar Therapeutics Shares Delivered a Stupendous 124% in November - Motley FoolWhy Nektar Therapeutics Shares Delivered a Stupendous 124% in November - Motley Fool
www.fool.com - December 5 at 5:10 PM
Why Nektar Therapeutics Shares Delivered a Stupendous 124% in NovemberWhy Nektar Therapeutics Shares Delivered a Stupendous 124% in November
www.fool.com - December 4 at 8:51 PM
-$0.35 Earnings Per Share Expected for Nektar Therapeutics (NKTR) This Quarter-$0.35 Earnings Per Share Expected for Nektar Therapeutics (NKTR) This Quarter
www.americanbankingnews.com - December 4 at 1:32 AM
Nektar Therapeutics: Positive Data from Phase 3 NKTR-181 TrialNektar Therapeutics: Positive Data from Phase 3 NKTR-181 Trial
finance.yahoo.com - November 30 at 10:05 AM
Hold On To Nektar Therapeutics: There Is Much More Ammunition ... - Seeking AlphaHold On To Nektar Therapeutics: There Is Much More Ammunition ... - Seeking Alpha
seekingalpha.com - November 29 at 5:33 PM
Nektar’s NKTR-358 Collaboration with Eli Lilly Boosted RevenuesNektar’s NKTR-358 Collaboration with Eli Lilly Boosted Revenues
finance.yahoo.com - November 29 at 9:45 AM
Nektar to Webcast Presentation at the Piper Jaffray 29th Annual Healthcare ...Nektar to Webcast Presentation at the Piper Jaffray 29th Annual Healthcare ...
www.prnewswire.com - November 28 at 10:20 AM
Is the Options Market Predicting a Spike in Nektar (NKTR) Stock?Is the Options Market Predicting a Spike in Nektar (NKTR) Stock?
finance.yahoo.com - November 28 at 10:20 AM
Nektar Therapeutics (NKTR) Sees Large Decline in Short InterestNektar Therapeutics (NKTR) Sees Large Decline in Short Interest
www.americanbankingnews.com - November 28 at 3:02 AM
Nektar to Webcast Presentation at the Piper Jaffray 29th Annual Healthcare Conference in New York CityNektar to Webcast Presentation at the Piper Jaffray 29th Annual Healthcare Conference in New York City
finance.yahoo.com - November 27 at 4:47 PM
Nektar Therapeutics (NKTR) Reports Phase III Study with Amikacin Inhale Does Not Meet Primary Endpoint of Superiority - StreetInsider.comNektar Therapeutics (NKTR) Reports Phase III Study with Amikacin Inhale Does Not Meet Primary Endpoint of Superiority - StreetInsider.com
www.streetinsider.com - November 26 at 9:23 AM
Nektar Therapeutics (NKTR) Price Target Raised to $45.00Nektar Therapeutics (NKTR) Price Target Raised to $45.00
www.americanbankingnews.com - November 26 at 12:52 AM

SEC Filings

Nektar Therapeutics (NASDAQ:NKTR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Nektar Therapeutics (NASDAQ:NKTR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Nektar Therapeutics (NASDAQ NKTR) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.